Drugs Controller General of India
Drugs Controller General of India ▸ Facts ▸ Comments ▸ News ▸ Videos
Drugs Controller General of India (DCGI) is the head of department of the Central Drugs Standard Control Organization of the Government of India responsible for approval of licences of specified categories of drugs such as blood and blood products, IV fluids, vaccines, and sera in India. Drugs Controller General of India, comes under the Ministry of Health & Family Welfare. DCGI also sets standards for manufacturing, sales, import, and distribution of drugs in India.
Covid update: Decongesting jails; DRDO's new oral drug; task force for oxygen
Credit: HT Digital Content Duration: 03:24Published
DCGI approves DRDO's anti-COVID drug helpful in faster recovery
Credit: ANI Duration: 02:44Published
What is 2-DG: New drug approved for Covid emergency use | Oneindia News
Credit: Oneindia Duration: 01:24Published
Zydus' Virafin gets emergency use approval for treating moderate COVID-19 cases
Credit: ANI Duration: 02:01Published
You Might Like
Potential cancer drug repurposed for Covid-19 by DRDO, Dr Reddy's gets DCGI nod for emergency useA potential cancer drug repurposed for Covid-19 treatment -- 2-deoxy-D-glucose (2-DG) – has received the Drugs Controller General of India (DCGI) nod for emergency use as adjunct therapy for..
DCGI approves anti-Covid drug developed by DRDO for emergency useThe Drugs Controller General of India’s (DCGI) has approved an anti-Coviddrug - 2-deoxy-D-glucose (2-DG) for emergency use. This has been developed by the Institute of Nuclear Medicine and Allied..
Also reported by •DNA
Bharat Biotech seeks DCGI's nod to extend shelf life of Covaxin
Zydus Cadila gets DCGI nod for hepatitis drug for Covid-19 treatmentDrug firm Zydus Cadila on Friday said it has received restricted emergency use approval from the Indian drug regulator for the use of Pegylated Interferon alpha-2b (PegIFN) in treating moderate..
Zydus Cadila's 'Virafin' gets DCGI nod for emergency use to treat COVID-19 patientsThe company has said that 91.15 per cent of patients treated with the drug were RT-PCR negative by day seven.
Health ministry issues regulatory pathways for foreign-produced Covid-19 vaccinesThe Central Drugs Standards Control Organisation (CDSCO) headed by Drugs Controller General of India (DCGI) has explained that it prepare detailed guidelines specifying regulatory pathway for approval..
Sputnik V cleared for launch in India: Five things you need to know about Russian Covid-19 vaccineDr Reddy's Laboratories said on Tuesday it has received permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations...
Expert panel clears Sputnik V for ‘emergency use’, drug regulator’s nod expected soonAmid concerns about the need to step up Covid-19 vaccination, India is soon expected to get its third shot against the infection with the drug regulator’s subject expert committee on Monday..
Russia hopes approval to Sputnik-V vaccine by DCGI will be completed soonRussia on Monday hoped that the Drug Controller General of India (DCGI) will soon complete the approval process for the Sputnik-V coronavirus vaccine after it was recommended for use in India by a..
Covid-19: Government's expert panel allows clinical trials for third dose of CovaxinBharat Biotech presented amendments to the subject expert committee of the Drugs Controller General of India (DCGI) in the approved Phase 2 clinical trial protocol for administration of booster dose..
Dr Reddy's initiates process for emergency use authorisation of Sputnik VDr Reddy's Laboratories said on Friday it has initiated the process with the Drugs Controller General of India (DCGI) for emergency use authorisation of human adenoviral vector-based platform vaccine..
Serum Institute seeks DCGI nod for clinical trials of Covid-19 vaccine Covavax
Bharat Biotech to begin Phase-1 trials of its intranasal vaccine for Covid-19 in Feb-MarchBuoyed by the Emergency Use Authorisation approval from the Drug Controller General of India (DCGI)for its Covid-19 vaccine Covaxin, Bharat Biotech has said Phase-1 clinical trials of its new..
From abroad, Rahul directing Cong rumour-mongering: BJPIntensifying attack on Congress for questioning the DCGI’s approval to Covid vaccines, BJP on Monday said Rahul Gandhi, while on a vacation abroad, choreographed rumour-mongering by enlisting his..
DCGI allows Bharat Biotech to conduct vaccine trials on children above 12Covaxin has already been used on children above 12 in phase I and II trials and has been found safe.
Like Putin and Joe Biden, PM Modi should also get the first vaccine shot, says Cong leaderThe DCGI on Sunday approved Serum Institute of India's 'Covishield' vaccine and Bharat Biotech's 'Covaxin' for emergency use.
Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for Covid-19 vaccine
Great milestone in India's scientific capability: Bharat Biotech after DCGI approval to CovaxinThe Hyderabad-based vaccine maker expressed its delight after DCGI granted permission for emergency use of its Covid-19 vaccine.
Covid-19 vaccines 110% safe, impotency rumours complete nonsense: DCGIAs India gears up for the world's largest vaccination programme, the Drugs Controller General of India (DCGI) on Sunday quelled rumours surrounding the Covid-19 vaccines regarding impotency, rubbishing..
'Watershed moment in India's battle against COVID': Politicos react over emergency use approvalDCGI approved Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use.
'Proud that two made in India vaccines given emergency use approval': PM Modi after DCGI nodPM Modi also extended his gratitude to doctors, medical staff, scientists, sanitation workers and all 'Corona warriors' for the outstanding work.
Covishield COVID-19 vaccine ready to roll out in coming weeks: SII's Adar PoonawallaPoonawalla's remarks came soon after DCGI approved Serum Institute's 'Covishield' vaccine for restricted emergency use in India.
DCGI approves Oxford's Covishield and Bharat Biotech's Covaxin vaccines for restricted emergency use
BREAKING: DCGI grants approval to Serum Institute, Bharat Biotech's COVID-19 vaccinesThe approval comes after the clearances from the Subject Expert Committee (SEC).
Bharat Biotech’s Covaxin too gets nod for emergency useIndia's vaccine rollout will begin with the availability of two jabs- Oxford-Astra Zeneca's Covishield and Bharat Biotech's homegrown Covaxin- with the Drugs Controller General of India expected to..
Covaxin vaccine: DCGI panel to meet Bharat Biotech officials shortly
Happy New Year: Expert panel clears Oxford vaccine for IndiaIndia moved closer to the rollout of its vaccination plan against Covid-19 with the subject expert committee of the drug regulator on Friday recommending emergency-use authorisation (EUA) for Serum..
Probably we will have a very happy New Year: DCGI on Covid-19 vaccineIndia is likely to have a Covid-19 vaccine in the New Year, Drug Controller General of India V G Somani hinted on Thursday. Speaking at a webinar, Somani said the most important thing is that the..
Zydus Cadila gets permission from DCGI for phase-1 clinical trial of novel molecule ZYIL1Drug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical trial of its novel molecule ZYIL1, indicated for use as an..
COVID-19 vaccine: Serum Institute seeks emergency use authorisation for Covishield in IndiaThe Serum Institute of India is the second company with a COVID-19 vaccine candidate to seek emergency use authorisation from the DCGI in India.
Also reported by •IndiaTimes
Pfizer becomes first pharma company in India to seek emergency use nod for its Covid-19 vaccinePfizer India has become the first pharmaceutical firm to approach the Drugs Controller General of India (DCGI) seeking an emergency use authorisation for its Covid-19 vaccine in the country. It is to..
DCGI finds no link between Covid vaccine shot and 'adverse' reaction in Chennai volunteer during trial: Sources
COVID-19 vaccine: Covidshield may be ready for rollout by Dec, says Serum Institute CEOCovidshield has shown promising results during trials, but a lot depends on the approvals coming through from the Drugs Controller General Of India.
ICMR issues advisory on CRISPR technology-based SARS CoV-2 testThe Indian Council of Medical Research (ICMR) on Thursday issued an advisory on the CRISPR SARS CoV-2 test that has been approved by the Drugs Controller General of India for Covid-19 detection. As..
Russian Sputnik V Covid-19 vaccine to be tested on 100 Indian volunteersThe Russian Sputnik V vaccine against Covid-19 will be tested in India on 100 volunteers, the Indian Central Drugs Standard Control Organisation's Drug Controller General (DCGI) told Sputnik on..
Dr Reddy's gets DCGI go-ahead to conduct Phase 2/3 human trials of Sputnik V in IndiaAfter the Indian drug regulator turned down Dr. Reddy’s Laboratories Ltd’s proposal earlier this month to conduct direct Phase-3 human trials for the Russian Covid-19 vaccine Sputnik V, the company..
Bharat Biotech asked to submit complete phase 2 data of its Covid-19 vaccine before phase 3 trialBharat Biotech, which had sought DCGI's nod for conducting phase-3 clinical trials of its Covid-19 vaccine candidate, has been asked to submit complete safety and immunogenicity data of the ongoing..
DCGI nod to Phase-1 human trials of 'antisera' with potential to treat Covid-19The Drugs Controller General of India has given permission for conducting Phase-1 human clinical trial for an "antisera" that was developed by injecting inactivated SARS-CoV-2 in horses and can be a..
Can Centre procure Rs 80,000 crore to buy, distribute COVID-19 vaccine across India? SII CEO Adar Poonawalla asksOn September 16, the Drugs Controller General of India (DCGI) allowed the Serum Institute of India (SII) to restart its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine.
Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nodThe Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine.
Serum Institute to resume vaccine trials after DCGI nod
Will resume Covid-19 vaccine trials after DCGI nod: Serum Institute
DCGI orders Serum Institute of India to suspend recruitment for Oxford Covid-19 vaccine trials
Serum pauses trials of Oxford vaccine after DCGI’s notice
Serum Institute gets DCGI notice over Oxford Covid-19 vaccine trial suspension by AstraZeneca abroadThe central drug regulator has issued a show-cause notice to Serum Institute of India (SII) for not informing it about pharma giant AstraZeneca pausing the clinical trials of the Oxford vaccine..
Covid-19: Subject Expert Committee seeks DCGI's nod to use hepatitis injection for phase III clinical trial